10 September 2015
The years-long glut of biotech IPOs has flooded the public markets with high-risk life sciences companies, and shorts have taken a particular interest in those newly public drug developers, according to a report, betting the industry's recent boom will see its shadow.
According to the Financial Times, small-cap biotech companies, on average, have about 7.3% of their shares in the hands of short sellers, a figure much higher than the Russell 3000 average of 4% and second only to the energy industry. And August's Wall Street swoon was a great time to short biotech: almost 90% of small-cap biotechs lost value last month, according to FT, and the biggest losers were heavily shorted.
But despite biotech's recent stumble, the industry is still in the midst of a longitudinal boom. The Nasdaq biotech ETF ($IBB) is up about 12% since the start of the year, and the S&P biotech ETF has risen 18% in the same period
And the pace of new IPOs has largely stayed on track. Nearly 40 life sciences companies have gone public in 2015, following 84 IPOs last year.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Health Ministry registered Russian drug for ankylosing spondylitis
06 May 2024
How gut enzymes could make universal donor blood possible
06 May 2024
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024